DYN

Dyne Therapeutics (DYN) has drawn fresh attention after releasing one year efficacy and safety data from the Phase 1/2 ACHIEVE trial of DYNE-101 in myotonic dystrophy type 1, highlighting functional gains compared with baseline and natural history cohorts.

Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) shares gained 2.1% in after-hours trading Tuesday following the release of one-year trial data for its experimental DM1 treatment z-basivarsen.

- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12…

Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 at upcoming World Muscle Society and AANEM meetings in late September and early October 2026.

Dyne Therapeutics (DYN) investment thesis remains intact despite a setback for Novartis (NVS) in a p

- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort -

Dyne Therapeutics (NASDAQ:DYN) shares fell 31. 0% to $16.

- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept.

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .